The KINOMEscan screening platform employs a novel and proprietary active site-directed competition binding assay to quantitatively measure interactions between test compounds and more than 450 kinase assays and disease relevant mutant variants. This robust and reliable assay technology affords investigators the ability to extensively annotate compounds with accurate, precise and reproducible data. KINOMEscan assays do not require ATP and thereby report true thermodynamic interaction affinities, as opposed to IC50 values, which can depend on the ATP concentration. KINOMEscan Platform Benefits & Features: Rapid turnaround time Largest commercially available kinase assay panel Flexible: screen any number of compounds against any number of kinases Custom panel capabilities to suppor...Read more
Receive your quote directly from DiscoveRx Corporation.
KINOMEscan Platform Benefits & Features: